Addressing the Challenges of AI is Imperative | AMCP Nexus 2024
There is a need for strict policies regarding the use of AI in the managed care space, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
As the use of AI progresses, it’s important that there are strict guidelines are in place for any ethical concerns that may arise, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
“[AI] is not going to stop, it's only going to get bigger and more prevalent,” Burgoyne said. “We have to put guardrails policies and procedures in place today to make sure that what we do tomorrow is the best we can do.”
Burgoyne attended AMCP Nexus 2024 last week, held at the MGM Grand in Las Vegas. He spoke at two sessions. The first was ‘AI in Healthcare: From Cutting Edge Innovations to Practical Applications in Formulary Decision Making.’ The second was called, ‘Executive to Executive: Leading Managed Care Organizations Today.’
AI Benefits PBMs, Health Plans and Formulary Decision Making | AMCP Nexus 2024
October 21st 2024Health plans and PBMs are using AI to aggregate data, summarize information and enhance their formulary decision-making processes, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
Read More
Technology can help address the complexities of specialty medications by automating processes and enabling proactive interventions to ensure patients stay on their critical therapies, according to Kristen Whelchel, Pharm.D., CSP, Research and Patient Care Improvement Pharmacist with Vanderbilt Specialty Pharmacy's Department of Health Outcomes and Research.
Read More
How Technology Benefits Specialty Pharmacy | AMCP 2024
October 18th 2024Kristen Whelchel, Pharm.D., CSP, Research and Patient Care Improvement Pharmacist with Vanderbilt Specialty Pharmacy's Department of Health Outcomes and Research, explains how technology identifies at-risk patients, coordinates medication refills and more.
Read More
Cancer’s Reign Over the Drug Development Pipeline Continues| AMCP Nexus 2024
October 18th 2024The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug pipeline talk at the 2024 AMCP Nexus meeting this week.
Read More
